title: A 5‑year update of patients with HPV positive versus negative oropharyngeal cancer after radiochemotherapy in Austria.
abstract: BACKGROUND
  After publishing promising results for the treatment of patients with human papilloma virus (HPV) positive oropharyngeal cancer with radiochemotherapy regarding 2‑year survival, we present an update of the disease-specific and disease-free survival after 5 years.
  
  
  METHODS
  A total of 29 patients of which 18 were HPV negative and 11 HPV positive with squamous cell carcinoma of the oropharynx received radiation therapy with or without chemotherapy (cisplatin) or immunotherapy (cetuximab) between 2007 and 2009. At time of the present analysis, six patients are still alive including four with HPV positive and two with HPV negative oropharyngeal carcinoma, while 15 out of 16 patients with HPV negative tumors died and 1 died of another cause with evidence of disease.
  
  
  RESULTS
  Since the 2‑year disease-specific survival of patients with HPV positive cancer of the oropharynx was published with 100% versus 30.4% in HPV negative tumors, we now present the 5‑year disease-specific survival after treatment, which was 85.7% in HPV positive versus 11.1% in HPV negative patients.
  
  
  CONCLUSIONS
  We present the results of patients receiving radiochemo(immuno)therapy for oropharyngeal cancer regarding the HPV status, which is still promising.
authors.affiliation: Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Claudia.lill@meduniwien.ac.at.
authors.forename: Claudia
authors.initials: C
authors.lastname: Lill
authors.affiliation: Rinecker Protone Therapy Center, Munich, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Bachtiary
authors.affiliation: Department of Radiotherapy, Medical University of Vienna, Vienna, Austria.
authors.forename: Edgar
authors.initials: E
authors.lastname: Selzer
authors.affiliation: Center for Medical Statistic, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
authors.forename: Martina
authors.initials: M
authors.lastname: Mittlboeck
authors.affiliation: Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.
authors.forename: Dietmar
authors.initials: D
authors.lastname: Thurnher
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001317:Austria / Q000453:epidemiology; D059248:Chemoradiotherapy / Q000401:mortality* / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000517:prevention & control; D009959:Oropharyngeal Neoplasms / Q000453:epidemiology* / Q000628:therapy*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013534:Survival; D016896:Treatment Outcome
keywords: Human papilloma virus; Oropharyngeal cancer; Radiochemotherapy; Update